AZX 100

Drug Profile

AZX 100

Alternative Names: AZX100

Latest Information Update: 28 Oct 2015

Price : $50

At a glance

  • Originator AzERx
  • Developer Capstone Therapeutics; OrthoLogic
  • Class Amino acids; Muscle relaxants; Peptides
  • Mechanism of Action Heat-shock protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Cerebral vasospasm; Pulmonary fibrosis; Scars; Vascular injuries

Most Recent Events

  • 26 Mar 2014 AZX 100 is available for licensing as of March 2014 (http://www.capstonethx.com)
  • 20 Jan 2012 Discontinued - Preclinical for Vascular injuries in USA (Parenteral)
  • 20 Jan 2012 Discontinued - Phase-II for Scars in USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top